Apolipoprotein E (apoE) is a multifunctional circulating 34-kDa protein, whose gene encodes single-nucleotide polymorphisms linked to several neurodegenerative diseases. Here, we evaluate whether synthetic RNA/DNA oligonucleotides (chimeraplasts) can convert a dysfunctional gene, APOE4 (C → T, Cys112Arg), a risk factor for Alzheimer's disease and other neurological disorders, into wild-type APOE3. In preliminary experiments, we treated recombinant Chinese hamster ovary (CHO) cells stably secreting apoE4 and lymphocytes from a patient homozygous for the ε4 allele with a 68-mer apoE4-to-apoE3 chimeraplast, complexed to the cationic delivery reagent, polyethyleneimine. Genotypes were analyzed after 48 h by routine polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and by genomic sequencing. Clear conversions of APOE4 to APOE3 were detected using either technique, although high concentrations of chimeraplast were needed (≥800 nM). Spiking experiments of PCR reactions or CHO-K1 cells with the chimeraplast confirmed that the repair was not artifactual. However, when treated recombinant CHO cells were passaged for 10 d and then subcloned, no conversion could be detected when >90 clones were analyzed by locus-specific PCR-RFLP. We conclude that the apparent efficient repair of the APOE4 gene in CHO cells or lymphocytes 48 h post-treatment is unstable, possibly because the high levels of chimeraplast and polyethyleneimine that were needed to induce nucleotide substitution are cytotoxic.
Introduction
Apolipoprotein E (apoE) is a circulating 34-kDa polymorphic protein that functions in plasma as an acceptor of cellular cholesterol and as a ligand to mediate hepatic clearance of lipoprotein remnant particles (Mahley and Ji, 1999; Mahley and Rall, 2000) . In cerebrospinal fluid, about half of all apolipoproteins are apoE (Koch et al., 2001 ), most being synthesized by astrocytes and microglia (Strittmatter and Bova Hill, 2002) . ApoE fulfills several functions, all mediated via receptor-dependent pathways, including maintenance of cholesterol homeostasis and local cholesterol redistribution within tissue undergoing repair or remodeling, developmental processes, and synapse formation (Beffert et al., 1998 (Beffert et al., , 2004 . The two common isoforms of apoE arise from nonsynonymous coding single-nucleotide polymorphisms (SNPs) of the wild-type APOE3 gene. The ε4 allele (15% frequency; C → T, Cys112Arg) is a strong risk factor for Alzheimer's disease (AD) and several chronic neurodegenerative diseases, whereas the rarest allele, ε2 (8% frequency, C → T, Arg158Cys), appears protective (Gasparini et al., 1998; Saunders, 2000) . The mechanism(s) underlying these associations is unknown, but might reflect isoform differences in intracellular apoE trafficking or in receptor-dependent cell-signaling pathways (Mahley and Rall, 2000; Strittmatter and Bova Hill, 2002; Sacre et al., 2003) .
Recently, synthetic RNA/DNA oligonucleotides have been used to repair point mutations in episomal and genomic DNA Richardson et al., 2002) . These reagents, often termed chimeraplasts, are double-stranded, hairpin-capped molecules that are designed to bind specifically to the defective DNA, enabling the cell's own repair machinery to recognize and correct the faulty DNA. Several groups have reported promising results using chimeraplasts (Cole-Strauss et al., 1996; Kren et al., 1998; Alexeev et al., 2000; Rice et al., 2001; Bertoni and Rando, 2002; Richardson et al., 2002) , including our own, which has successfully converted the dysfunctional APOE2 gene to wild-type APOE3, both in vitro and in vivo . Here, we apply chimeraplasty to recombinant Chinese hamster ovary (CHO) cells expressing human apoE4, as well as to cultured lymphocytes from a patient homozygous for the ε4 allele, in an attempt to convert mutant APOE4 to wild-type APOE3. Despite early encouraging results in short-term studies, we were unable to achieve consistent and reproducible conversions in the long term.
Materials and Methods

Cell Culture
The cloned CHO cell line expressing human apoE4 that was used in these studies was produced by the method described previously for CHO-E2 cells . These recombinant cells were cultured in Iscove's modified Dulbecco's medium with 10% dialyzed fetal bovine serum ([FBS] Sigma), supplemented with 2 mM glutaMAX and 1% nonessential amino acids (Life Technologies). Lymphocytes were isolated from the heparinized blood of a patient homozygous for the ε4 allele and immortalized with Epstein-Barr virus (EBV) (Negri et al., 1991) . These transformed cells were grown as suspension cultures in RPMI 1640 medium, supplemented with 10% FBS and 2 mM L-glutamine.
Chimeraplasty and Transfections
The RNA/DNA oligonucleotides were synthesized commercially by MWG-Biotech (Ebersberg, Germany) to designs dictated by the target DNA (Fig. 1A) . One strand of the self-associating duplex, termed the targeting strand (Gamper et al., 2000) , had 10 complementary 2'-O-methyl RNA residues flanking each side of the 5-base DNA stretch. The protected RNA bases resisted RNase H-mediated degradation, whereas four T-residues in each loop and a 5-bp GC clamp ensured that they self-associated into a double hairpin. The other correcting strand was all DNA and, except for the intended base mismatch, was complementary to the genomic DNA target. Cells were seeded into 6-well plates (2 × 10 5 cells/well) 24 h prior to transfections. Chimeraplasts (400-1000 nM) were preincubated for 10 min with linear 22-kDa polyethyleneimine (PEI) (ExGen 500; TCS Biologicals Ltd.) at different amine: phosphate molar ratios (5:1-9:1) and with the addition of 150 mM NaCl. The complexes (50 µL) were then added to each well of cells growing in 0.5 mL of serum-containing medium. After 4-6 h, monolayers were washed with phosphate-buffered saline and incubated with 2 mL of fresh medium for 48 h prior to harvesting the cells and extracting genomic DNA. In the long-term experiments, we continued to passage and culture cells for 10 d before isolating clones by limiting dilution and ring cloning.
ApoE Genotyping and DNA Sequencing
Genomic DNA (DNeasy kit; Qiagen) was extracted from cells for routine polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) genotyping (Hixson and Vernier, 1990) , amplifying a 227-bp product by 36 cycles (94ºC for 30 s and 68ºC for 30 s) with the primer pair, 5'-TCCAAGGAGCTGCAGGCGGCGCA-3' (sense) and 5'-ACAGAATTCGCCCCGGCCTGGTA-CACTGCCA-3' (antisense), and separating the HhaI-digested fragments on 20% Tris-buffered EDTA-polyacrylamide gels (Invitrogen). Each genotype gave a specific combination of HhaI fragment sizes: apoE2, 91 and 83 bp; apoE3, 91 and 48 bp; and apoE4, 72 and 48 bp (Fig. 1B) . A locus-specific PCR was also devised to avoid the appearance of ambiguous fragments, which often result from routine PCR-RFLP analyses involving the apoE4 genotype (Wu et al., 2000) . This involved 36 cycles of PCR (94ºC for 30 s and 68ºC for 30 s) with the primer pair, 5'-AGGCCCGGCTGGGCGTGGA-3' (sense) and 5'-TGGGAGGCGAGACGCACCCG-3' (antisense), and was designed to amplify a region around the E4/E3 locus while abolishing two HhaI restriction sites. The final 118-bp product contains only one
Fig. 1. Chimeraplast design and apoE genotype analysis by PCR-RFLP. (A)
The sequence of the apoE4-to-E3 chimeraplast, which is internally matched , is shown with the DNA residues in uppercase letters, and the 2'-O-methylated RNA bases in lowercase. The all-DNA correcting strand is underlined, with the central mutating residue double-underlined; the DNA mutator region of the targeting strand is shown in bold. (B) Routine genotyping (Hixson and Vernier, 1990) was performed by amplifying a 227-bp PCR product from exon IV and restriction isotyping with HhaI. Cleavage sites for HhaI are shown by arrows and are given for apoE2-, apoE3-, and apoE4-amplified sequences; codons 112 and 158 are depicted as filled boxes. (C) Locus-specific PCR-RFLP was introduced to avoid ambiguities arising from routine genotyping. E4/E3 locus-specific primers were designed to amplify a smaller fragment while abolishing two HhaI sites during PCR. The complete sequence of the 118-bp product, encompassing the E4/E3 locus, which was targeted by PCR, is shown; the residues matching the PCR primers are in bold, and the two C nucleotides, which are modified during PCR to T, are underlined. The four nucleotides in bold (GCGC) between the primer pair denote the only HhaI site now left in the PCR product, with the underlined cytosine being the nucleotide targeted by chimeraplasty.
HhaI site compared with the four to six present in the 227-bp product generated during routine PCR-RFLP analysis (Fig. 1B) . Each genotype gave a specific combination of HhaI fragment sizes following digestion and separation on 20% Tris-buffered EDTA-polyacrylamide gels: apoE4, 85 and 33 bp; apoE3, 118 bp; and apoE4/E3, 118, 85, and 33 bp. The sense primer from the routine PCR-RFLP analysis and antisense primer from the locus-specific analysis were used for automated DNA sequencing of purified PCR products.
Spiking Experiments
Two different experiments were designed to evaluate if the chimeraplast, whether intact or degraded, could function as a primer or template in the PCRbased analyses. In the first study, increasing amounts of intact chimeraplast (3 pg-300 ng) were added directly to the PCR mix, which also contained 100 ng of CHO-E4 DNA. In the second study, CHO-K1 cells were transfected with different amounts of apoE4-to-E3 chimeraplast (600-1000 nM), and 24-48 h later DNA was extracted and mixed 1:1 with CHO-E4 or E4-lymphocyte DNA; 100 ng of this total DNA was used in the standard 25-µLPCR reaction. Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analyses were performed as outlined above.
Results
Short-Term Conversion of APOE4 TO APOE3
in Recombinant CHO Cells and Human Lymphocytes Subconfluent CHO-E4 cells were treated with a 68-mer apoE4-to-E3 chimeraplast (Fig. 1A) , at a range of concentrations and amine to phosphate (PEI: RNA/DNA oligonucleotide) molar ratios. A clear conversion was seen at each concentration tested using routine PCR-RFLP (Hixson and Vernier, 1990) (Fig. 1B) , although the most efficient conversion was achieved at 800 nM and an 8:1 amine:phosphat molar ratio ( Fig. 2A) . These conversions were confirmed by direct sequencing (Fig.  2B-E) , whereas the same apoE4-to-E3 chimeraplast was used as a negative control and had no effect on CHO-E2 cells (Fig. 2A) .
The APOE4 gene was also targeted in cultured lymphocytes from a homozygous ε4/ε4 patient for 16 h with increasing concentrations (400-1000 nM) of PEI/chimeraplast at amine: phosphate molar ratios of 5:1-7:1. A clear conversion of 98 Tagalakis et al.
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Volume 25, 2005 APOE4 to APOE3 was seen at 800 and 1000 nM, whereas the genotype of E2 lymphocytes, used as a negative control, was unchanged (Fig. 3A) . A 7:1 ratio of PEI to oligonucleotide and 800 nM of chimeraplast gave the highest conversion, and this was confirmed by direct sequencing (Fig. 3B-E) . However, analyses of the conversions by PCR-RFLP for both cell types were complicated by the appearance of an additional unexpected band at 83 bp. This unexpected band might reflect partial digestion, and its frequent appearance has been noted previously during routine genotyping of apoE4/E3 or apoE4/E4 patients (Wu et al., 2000) .
To circumvent this problem a new locus-specific PCR-RFLP was devised (Fig. 1C) and used in selected studies.
APOE4 to APOE3 Gene Conversion by Chimeraplasty Is Not Artifactual
Two methods were employed to investigate whether APOE4-to-APOE3 conversions could be attributed to PCR artifacts. First, increasing amounts (1 pg-300 ng) of intact apoE4-to-E3 chimeraplast were mixed into a standard PCR-RFLP reaction containing 100 ng of DNA extracted from CHO-E4 cells. This procedure did not give rise to a PCR-generated artifact, as no diagnostic apoE3 band (91 bp) appeared (Fig. 4A) . Second, CHO-K1 cells were transfected with varying amounts of apoE4-to-E3 chimeraplast (600-1000 nM); 48 h later, DNA was extracted from the cells and mixed 1:1 with CHO-E4 or E4-lymphocyte DNA. Again, there was no evidence Fig. 2 . Conversion of apoE4 cDNA in stably transfected recombinant CHO cells to apoE3 by chimeraplasty. (A) Clear conversions of apoE4-to-apoE3 cDNA (C → T) were seen 48 h after transfecting recombinant CHO-E4 cells with the 68-mer apoE4-to-E3 chimeraplast at 800 nM at increasing amine/phosphate (PEI/RNA/DNA oligonucleotide) molar ratios (6:1-8:1), as judged by the appearance of the diagnostic 91-bp band. (B-E) Sequencing chromatograms of chimeraplasttreated CHO-E4 cells. As expected, the untreated CHO-E4 cells (B) had only a C at the respective codon (112) of the apoE cDNA (arrow), whereas partial gene conversion was evident in CHO-E4 cells treated with 800 nM of chimeraplast, as the T expected for apoE3 was additionally present (C-E). The highest conversion (E) was seen at an amine/phosphate molar ratio of 8:1 (E), whereas lower conversion efficiencies were observed at ratios of 6:1 (C) and 7:1 (D).
of any artifactually produced band, this time using locus-specific PCR-RFLP analysis, implying that any intracellular degradation products do not act as PCR templates or primers (Fig. 4B) .
Unsuccessful Long-Term apoE-to-apoE3
Conversion in CHO-E4 Cells Chinese hamster ovary E4 (CHO-E4) cells were transfected with 800 nM apoE4-to-E3 chimeraplast at an amine/phosphate ratio of 8:1, which gave optimal conversion ( Fig. 2A) , and maintained in culture for 10 d, passaging every other day. The cells were then cloned by limiting dilution and ring isolation, expanded, and their cellular DNA extracted for analysis by locus-specific PCR-RFLP and for some clones by direct sequencing. No conversion to apoE3 was detectable by PCR-RFLP analysis for any of the 93 clones examined (Fig. 5A) . Direct DNA sequencing confirmed that the genotypes were unchanged and provided no evidence that any of the individual clones analyzed might have been converted to the apoE3 genotype (Fig. 5B) .
Discussion
Chimeraplast-directed substitution of single bases within a gene is a powerful technology with enormous potential. Importantly, like other tissues and organs, the brain is amenable to gene transfer (Shi et al., 2001 ). Conversion of apoE4-expressing cells to apoE3 is an intriguing possibility; the ε4 allele is strongly associated with AD and a variety of other neurodegenerative disorders (Gasparini et al., 1998; Saunders, 2000) and also predicts poor prognosis in Fig. 3 . Converting genomic APOE4 to APOE3 in human lymphocytes. (A) Clear conversion of the APOE4 gene to APOE3 (C → T) was seen 48 h after transfecting EBV-transformed lymphocytes from a patient homozygous for the ε4 allele with the 68-mer apoE4-to-E3 chimeraplast using increasing oligonucleotide concentrations and different amine/phosphate molar ratios, as judged by the appearance of the diagnostic 91-bp band. Ladder, 10-bp markers; E2-control, lymphocytes from an ε2/2 patient treated with the apoE4-to-E3 chimeraplast. (B-E) Sequencing chromatograms of chimeraplast-treated E4-lymphocytes. Partial gene conversion was confirmed (B) by direct sequencing of the PCR product from treated E4 lymphocytes (800 nM, 6:1 amine/phosphate molar ratio), as the T predicted for apoE3 was present as well as the C of apoE4. The highest conversion (C) was seen at 800 nM and a 7:1 amine/phosphate molar ratio; lower conversions were noted at 1000 nM and at 6:1 (D) or 7:1 (E) amine/phosphate molar ratios. traumatic brain injury (Kay et al., 2003) . Therefore, targeting the APOE4 gene in brains of patients with AD to express apoE3 (or apoE2) could prove beneficial and an attractive therapeutic possibility, which could be explored first in transgenic mice expressing human apoE4 (Xu et al., 1996; Gong et al., 2002) .
Here, in short-term preliminary experiments, we targeted recombinant CHO cells expressing apoE4 with a 68-mer apoE4-to-E3 chimeraplast of standard design . Evidence for a successful conversion of the APOE4 gene was obtained by PCR-RFLP analysis (91-, 72-, and 48-bp bands) and by direct sequencing of the PCR product, which showed an apoE4/E3 genotype for treated cells. Genomic APOE4 was also targeted in cultured transformed lymphocytes from a homozygous ε4/ε4 patient using the same chimeraplast; clear conversion to the apoE4/E3 genotype was seen by PCR-RFLP and confirmed by sequencing. These conversions did not occur through a PCR artifact. The diagnostic band did not appear in spiking experiments when the chimeraplast was added directly to the PCR mix or when DNA extracted from transfected CHO-K1 cells, which potentially contained degraded chimeraplast fragments, was used in the PCR reaction. Therefore, we reject the possibility that intact chimeraplasts, or chimeraplast degradation products generated intracellularly, can act as primers and/or template, as suggested by some researchers (Thomas and Capecchi, 1997; Zhang et al., 1998) .
When CHO-E4 cells were cultured for 10 d after chimeraplasty and then cloned, no conversion was detected in >90 clones analyzed by locus-specifc PCR-RFLP. This longer-term study implied that the conversion to APOE3 was not stable, in contrast with our previous finding for APOE2-to-APOE3 gene repairs or the reports of other researchers targeting different genes (Kren et al., 1998; Alexeev et al., 2000; Bertoni and Rando, 2002) . One explanation for this apparent instability might be an irreversible cytotoxic action of the transfection complex on the CHO-E4 cells, perhaps making them vulnerable to apoptosis. Consistent with this possibility, we found that the concentration of apoE4-toapoE3 chimeraplast needed for successful conversion was high (800 or 1000 nM; Figs. 2 and 3), whereas our previous conversions with apoE2-toapoE3 chimeraplasts were accomplished efficiently with lower concentrations (200 or 400 nM) ). Thus, a twofold or greater increase in chimeraplast, or, perhaps more significantly, its carrier PEI, which has potential cyotoxicity (Fischer et al., 1999; Olsen et al., 2003) , might have contributed to the instability of the repair. An alternative, though less likely, explanation is that the switch from an apoE4 to an apoE3 phenotype promoted cell death, perhaps because of a difference in intracellular trafficking of the two apoE isoforms (Strittmatter and Bova Hill, 2002; DeKroon and Armati, 2001 ). However, it should also be noted that our cloning analysis might have missed low-level stable conversions of ≤1%, which have been reported previously in mammalian cells using sensitive reporter gene assays (Thorpe et al., 2002a; Nickerson and Colledge, 2003; Tran et al., 2003) .
Our current failure to achieve detectable longterm correction of the dysfunctional APOE4 gene mirrors several recent reports highlighting failure or poor reproducibility when targeting other genes (Albuquerque-Silva et al., 2001; Van der Steege et al., 2001; Taubes, 2002) . This is perhaps not entirely unexpected, as the technology is relatively new and evolving with many factors yet to be optimized Yoon et al., 2002) . One problem might be the quality of the chimeraplast itself; the reagents are long molecules that tend to self-associate during synthesis, both features that would promote formation of N-1 failure fragments and other impurities (Manzano et al., 2003) . The higher concentration of chimeraplast needed to convert APOE4 to APOE3, compared with APOE2 to APOE3, conversions ) might simply reflect a lower quality reagent. An additional problem, in some ways common to general gene therapy strategies, is to ensure efficient delivery to the cell nucleus (and in vivo to the target organ itself), avoiding reagent degradation or cytotoxic effects (Ogris and Wagner, 2002) . Finally, more work is needed regarding basic mechanisms by which cells accomplish mismatch repair, an area about which we remain largely ignorant. Stimulation of repair by synchronizing cell cycles to the S-phase (Majumdar et al., 2003) , or by increasing expression of RAD51 (Liu et al., 2001; Thorpe et al., 2002a Thorpe et al., , 2002b , appears to be a useful starting point for improving efficiency. Given the enormous potential of oligonucleotide-directed gene repair, it is hoped that such developments will allow progress to treat disease caused by point mutations, including neurodegenerative disorders associated with the ε4 allele. There was no evidence for conversion of the G in apoE4 (circled) to the A expected for apoE3.
